Outcome of Board Meeting pertaining to Sub-Division/Split of Equity Shares of Company.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors of Titan Biotech Limited, at its meeting held on November 29, 2025, approved the sub-division (split) of equity shares in the ratio of 1:5. Each existing equity share with a face value of Rs. 10 will be split into 5 equity shares with a face value of Rs. 2 each. Post-split, the paid-up equity share capital will increase from 82,63,700 shares of Rs. 10 to 4,13,18,500 shares of Rs. 2. The rationale stated is to enhance liquidity and make shares more affordable for retail investors. The split is subject to shareholder approval via postal ballot and other regulatory approvals. The record date will be announced after shareholder approval, and the process is expected to be completed within two months of that approval.
Stock splits typically improve liquidity and lower the per-share price, making the stock more accessible to retail investors. Existing shareholders' overall value and percentage holdings remain unchanged, though the share price will adjust downward proportionally once the split is effective.